-

Shareholder Alert: Robbins LLP Announces It Is Investigating ADTRAN, Inc. (ADTN)

SAN DIEGO & HUNTSVILLE, Ala.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces it is investigating ADTRAN, Inc. (NASDAQ: ADTN) for alleged violations of the Securities Exchange Act of 1934 and whether Company officers and directors breached their fiduciary duties to shareholders. ADTRAN is a networking and communications company that provides services which enable voice, data, video, and internet communications across a variety of network infrastructures.

If you suffered a loss as a result of ADTRAN's misconduct, click here.

ADTRAN, Inc. (ADTN) Misled Shareholders

On August 12, 2019, ADTRAN disclosed that it was unable to timely file its quarterly financial report with the SEC due to a material weakness in the Company's internal control that resulted in a misstatement of its excess and obsolete inventory reserves. Despite touting its ability to maintain sufficient inventory levels, on October 9, 2019, ADTRAN announced that its revenue had been "significantly impacted" by a pause in shipments to a customer in Latin America. Following all these disclosures, ADTRAN's stock price fell 44% to close at $8.81 on October 10, 2019, and has yet to recover.

ADTRAN, Inc. (ADTN) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click Here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:ADTN

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Eos Energy Enterprises, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Eos Energy Enterprises, Inc. (NASDAQ: EOSE) securities between November 5, 2025 and February 26, 2026. Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems intended for utility-scale commercial and industrial applications. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a n...

Investor Notice: Robbins LLP Informs Investors of the Aquestive Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025 and January 8, 2026. Aquestive is a pharmaceutical company committed to advancing medicines to bring improvement to patients’ lives through innovative science and delivery technologies. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a...
Back to Newsroom